» Articles » PMID: 23774593

Group B Streptococcus and Streptococcus Suis Capsular Polysaccharides Induce Chemokine Production by Dendritic Cells Via Toll-like Receptor 2- and MyD88-dependent and -independent Pathways

Overview
Journal Infect Immun
Date 2013 Jun 19
PMID 23774593
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Streptococcus agalactiae (also known as group B Streptococcus [GBS]) and Streptococcus suis are encapsulated streptococci causing severe septicemia and meningitis. Bacterial capsular polysaccharides (CPSs) are poorly immunogenic, but anti-CPS antibodies are essential to the host defense against encapsulated bacteria. The mechanisms underlying anti-CPS antibody responses are not fully elucidated, but the biochemistry of CPSs, particularly the presence of sialic acid, may have an immunosuppressive effect. We investigated the ability of highly purified S. suis and GBS native (sialylated) CPSs to activate dendritic cells (DCs), which are crucial actors in the initiation of humoral immunity. The influence of CPS biochemistry was studied using CPSs extracted from different serotypes within these two streptococcal species, as well as desialylated CPSs. No interleukin-1β (IL-1β), IL-6, IL-12p70, tumor necrosis factor alpha (TNF-α), or IL-10 production was observed in S. suis or GBS CPS-stimulated DCs. Moreover, these CPSs exerted immunosuppressive effects on DC activation, as a diminution of gamma interferon (IFN-γ)-induced B cell-activating factor of the tumor necrosis factor family (BAFF) expression was observed in CPS-pretreated cells. However, S. suis and GBS CPSs induced significant production of CCL3, via partially Toll-like receptor 2 (TLR2)- and myeloid differentiation factor 88 (MyD88)-dependent pathways, and CCL2, via TLR-independent mechanisms. No major influence of CPS biochemistry was observed on the capacity to induce chemokine production by DCs, indicating that DCs respond to these CPSs in a patterned way rather than a structure-dedicated manner.

Citing Articles

Combinatorial multimer staining and spectral flow cytometry facilitate quantification and characterization of polysaccharide-specific B cell immunity.

Hoving D, Marques A, Huisman W, Nosoh B, de Kroon A, van Hengel O Commun Biol. 2023; 6(1):1095.

PMID: 37898698 PMC: 10613281. DOI: 10.1038/s42003-023-05444-3.


Immunogenicity and Protective Potential of Mucosal Vaccine Formulations Based on Conserved Epitopes of Influenza A Viruses Fused to an Innovative Ring Nanoplatform in Mice and Chickens.

Calzas C, Mao M, Turpaud M, Viboud Q, Mettier J, Figueroa T Front Immunol. 2021; 12:772550.

PMID: 34868036 PMC: 8632632. DOI: 10.3389/fimmu.2021.772550.


Streptococcus-associated vasculitis: A role for antibiotic therapy?.

Saad R, Tsoi K, Onac I, Davies K, Hajela V, Tacu C IDCases. 2021; 24:e01071.

PMID: 33777696 PMC: 7985411. DOI: 10.1016/j.idcr.2021.e01071.


Comparative Study of Immunogenic Properties of Purified Capsular Polysaccharides from Serotypes 3, 7, 8, and 9: the Serotype 3 Polysaccharide Induces an Opsonizing IgG Response.

Goyette-Desjardins G, Auger J, Dolbec D, Vinogradov E, Okura M, Takamatsu D Infect Immun. 2020; 88(10).

PMID: 32747605 PMC: 7504959. DOI: 10.1128/IAI.00377-20.


Immunological Characteristics in Refractory Chronic Rhinosinusitis with Nasal Polyps Undergoing Revision Surgeries.

Ryu G, Kim D, Dhong H, Eun K, Lee K, Kong I Allergy Asthma Immunol Res. 2019; 11(5):664-676.

PMID: 31332978 PMC: 6658403. DOI: 10.4168/aair.2019.11.5.664.


References
1.
Kerdsin A, Oishi K, Sripakdee S, Boonkerd N, Polwichai P, Nakamura S . Clonal dissemination of human isolates of Streptococcus suis serotype 14 in Thailand. J Med Microbiol. 2009; 58(Pt 11):1508-1513. DOI: 10.1099/jmm.0.013656-0. View

2.
Segura M, Gottschalk M, Olivier M . Encapsulated Streptococcus suis inhibits activation of signaling pathways involved in phagocytosis. Infect Immun. 2004; 72(9):5322-30. PMC: 517481. DOI: 10.1128/IAI.72.9.5322-5330.2004. View

3.
Moon E, Lee J, Oh S, Ryu S, Kim H, Kwak H . Reactive oxygen species augment B-cell-activating factor expression. Free Radic Biol Med. 2006; 40(12):2103-11. DOI: 10.1016/j.freeradbiomed.2006.02.007. View

4.
Koenig J, Keenan W . Group B streptococcus and early-onset sepsis in the era of maternal prophylaxis. Pediatr Clin North Am. 2009; 56(3):689-708, Table of Contents. PMC: 2702484. DOI: 10.1016/j.pcl.2009.04.003. View

5.
Elliott S, Clifton-Hadley F, Tai J . Streptococcal infection in young pigs. V. An immunogenic polysaccharide from Streptococcus suis type 2 with particular reference to vaccination against streptococcal meningitis in pigs. J Hyg (Lond). 1980; 85(2):275-85. PMC: 2133920. DOI: 10.1017/s0022172400063312. View